Anything new in EU pharmacovigilance? - Suppr | 超能文献

Anything new in EU pharmacovigilance?

作者信息

Garattini Silvio, Bertele' Vittorio

出版信息

Eur J Clin Pharmacol. 2011 Nov;67(11):1199-200. doi: 10.1007/s00228-011-1052-1. Epub 2011 May 4.

DOI:10.1007/s00228-011-1052-1

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Anything new in EU pharmacovigilance?

Eur J Clin Pharmacol. 2011 Nov;67(11):1199-200. doi: 10.1007/s00228-011-1052-1. Epub 2011 May 4.

2

Looking at EU pharmacovigilance.

Eur J Clin Pharmacol. 2011 Nov;67(11):1201-2. doi: 10.1007/s00228-011-1074-8. Epub 2011 Jul 13.

3

Getting to grips with the new European Union pharmacovigilance legislation.掌握新的欧盟药物警戒法规。

Pharmacoepidemiol Drug Saf. 2011 May;20(5):544-9. doi: 10.1002/pds.2119.

4

Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.加强和合理化欧盟的药物警戒：欧洲将走向何方？对新的欧盟药物警戒立法的审查。

Drug Saf. 2011 Mar 1;34(3):187-97. doi: 10.2165/11586620-000000000-00000.

5

[Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].[临床试验中的不良反应记录与报告。依据修订德国药品法（AMG）的第12条法律及药物临床试验质量管理规范（GCP）条例的新法律规定]

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005 Feb;48(2):173-80. doi: 10.1007/s00103-004-0986-1.

6

[The new pharmacovigilance legislation in practice].[新药物警戒法规的实际应用]

Ned Tijdschr Geneeskd. 2014;158:A7129.

7

The new EU legislation on pharmacovigilance and changing models for drug development.欧盟关于药物警戒的新立法以及不断变化的药物研发模式。

Drug Saf. 2011 Jun 1;34(6):529-30; author reply 530-1. doi: 10.2165/11592380-000000000-00000.

8

EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.欧盟对抗癌生物类似单克隆抗体的药物警戒监管要求。

Int J Clin Pharm. 2018 Aug;40(4):778-782. doi: 10.1007/s11096-018-0709-6. Epub 2018 Aug 9.

9

Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.测量 2012 年欧洲药物警戒立法对额外风险最小化措施的影响。

Expert Opin Drug Saf. 2018 Oct;17(10):975-982. doi: 10.1080/14740338.2018.1512579. Epub 2018 Aug 22.

10

Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.巴西药物警戒法规的协调统一：改善风险沟通的机会。

Clin Ther. 2019 Mar;41(3):598-603. doi: 10.1016/j.clinthera.2019.01.013. Epub 2019 Feb 18.

引用本文的文献

1

European Union pharmacovigilance capabilities: potential for the new legislation.欧盟药物警戒能力：新法规的潜力

Ther Adv Drug Saf. 2015 Aug;6(4):120-40. doi: 10.1177/2042098615591802.

2

Looking at EU pharmacovigilance.

Eur J Clin Pharmacol. 2011 Nov;67(11):1201-2. doi: 10.1007/s00228-011-1074-8. Epub 2011 Jul 13.

本文引用的文献

1

Rosiglitazone and the need for a new drug safety agency.罗格列酮与对新药品安全机构的需求。

BMJ. 2010 Oct 6;341:c5506. doi: 10.1136/bmj.c5506.

2

Risk Management Plans: are they a tool for improving drug safety?风险管理计划：它们是提高药物安全性的工具吗？

Eur J Clin Pharmacol. 2010 Aug;66(8):785-90. doi: 10.1007/s00228-010-0848-8. Epub 2010 Jun 25.